Core Insights - Indaptus Therapeutics has made significant progress in 2024, particularly with its lead clinical candidate, Decoy20, which is an innovative immunotherapy targeting cancer and viral infections [1][2] - The company has established a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab, highlighting the potential of Decoy20 as both a standalone therapy and in synergy with existing treatments [3] - Indaptus raised $5.5 million in 2024 to support ongoing research and development efforts, ensuring financial stability for future initiatives [5] Clinical Developments - Decoy20 demonstrated a broad immune response across multiple tumor types in patients during its Phase 1 clinical trial, indicating its potential as a monotherapy [4] - The company initiated a higher-dose weekly regimen for Decoy20 after positive safety reviews, expanding the trial's scope to assess safety and efficacy [4] - Key presentations at major industry conferences, including AACR and ASCO, showcased promising preliminary results and immune activation in patients treated with Decoy20 [4] Future Outlook - Indaptus plans to advance Decoy20 through clinical trials in 2025, focusing on its combination potential with BeiGene's tislelizumab [6] - The company aims to open a combination cohort in its clinical trial and expand the number of participating clinical sites to enhance patient enrollment [9] - Upcoming milestones in the first half of 2025 are expected to represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform [7] Scientific Foundation - The Decoy platform is based on a multi-targeted approach to activate both innate and adaptive immune responses, utilizing engineered Decoy bacteria to enhance therapeutic applications [8] - Pre-clinical studies have shown Decoy product candidates' effectiveness against various cancers and chronic viral infections, indicating a strong scientific foundation for future developments [10]
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025